Sigachi Industries growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−2.1%+22.4%+32.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−46.2%+30.4%+30.5%
−57.1%+27.9%+26.4%
−217.5%+23.0%+31.5%
−203.9%+13.8%−87.2%
−0.6%+21.9%+85.7%
−13.7%+39.0%+64.3%
−84.0%+108.9%−55.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SIGACHI₹26.60

Sigachi Industries Limited

· Pharma & Health
₹ CrorePeersLINCOLNTHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYNGLFINEMcap ₹1,016 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+32.1+22.4-2.1—
EBITDA Growth—+30.5+30.4-46.2—
EBIT Growth—+26.4+27.9-57.1—
Net Income Growth—+31.5+23.0-217.5—
EPS Growth—-87.2+13.8-203.9—
Total Assets Growth—+85.7+21.9-0.6—
Total Equity Growth—+64.3+39.0-13.7—
Cash from Operations Growth—-55.6+108.9-84.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.